Ketek--the FDA perspective

N Engl J Med. 2007 Apr 19;356(16):1675-6. doi: 10.1056/NEJMc076135.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Advisory Committees
  • Anti-Bacterial Agents / adverse effects*
  • Chemical and Drug Induced Liver Injury*
  • Clinical Trials as Topic*
  • Drug Approval*
  • Humans
  • Ketolides / adverse effects*
  • Product Surveillance, Postmarketing
  • Scientific Misconduct
  • United States
  • United States Food and Drug Administration*

Substances

  • Anti-Bacterial Agents
  • Ketolides
  • telithromycin